These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 32203863)

  • 1. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
    Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
    Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis.
    Daniulaityte R; Nahhas RW; Silverstein S; Martins S; Zaragoza A; Moeller A; Carlson RG
    Drug Alcohol Depend; 2019 Nov; 204():107574. PubMed ID: 31568934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "The Doctor Says You Cannot Have [Buprenorphine]" Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine.
    Hayes BT; Jakubowski A; Fitzsimmons C; Garcia B; Ramirez F; Fox AD
    Subst Use Misuse; 2021; 56(8):1137-1143. PubMed ID: 33939937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl.
    Silverstein SM; Daniulaityte R; Martins SS; Miller SC; Carlson RG
    Int J Drug Policy; 2019 Dec; 74():76-83. PubMed ID: 31563098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "They're making it so hard for people to get help:" Motivations for non-prescribed buprenorphine use in a time of treatment expansion.
    McLean K; Kavanaugh PR
    Int J Drug Policy; 2019 Sep; 71():118-124. PubMed ID: 31330267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis.
    Daniulaityte R; Nahhas RW; Silverstein S; Martins S; Carlson RG
    J Subst Use Addict Treat; 2023 Apr; 147():208973. PubMed ID: 36804351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
    Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
    Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
    Johnson B; Richert T
    Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "They Ask Questions, But They Don't Want the Answers"-Perceptions of Clinical Communication Among Veterans Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder.
    Eckhardt A; Waller DE; Shull S; Lovejoy TI; Morasco BJ; Gordon AJ; Wyse JJ
    Subst Use Addctn J; 2024 Oct; 45(4):674-681. PubMed ID: 38767274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.
    Rubel SK; Eisenstat M; Wolff J; Calevski M; Mital S
    Subst Use Misuse; 2023; 58(5):685-697. PubMed ID: 36803159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users.
    Butler SF; Oyedele NK; Dailey Govoni T; Green JL
    JMIR Public Health Surveill; 2020 Mar; 6(1):e16038. PubMed ID: 32209533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
    Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
    JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
    Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
    Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
    Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
    J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
    Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
    J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Motivations for Nonprescribed Buprenorphine Use Among Rural Appalachian Substance Users.
    McDonald MJ; DeVeaugh-Geiss AM; Chilcoat HD; Havens JR
    J Addict Med; 2023 Jan-Feb 01; 17(1):95-100. PubMed ID: 36044288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.